The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of...
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease ...
Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers f...
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicit...
HERA will procure 175,420 doses for immediate response to the concerning mpox outbreak in Africa, and furthermore, Bavarian Nordic will donate 40,000 d...
NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria...
Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution, announced a license agre...
Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Funding will support clin...
Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Mill...
Biotechnology company Apriori Bio has been awarded US $1.1 million from CEPI to advance its biology-informed artificial intelligence platform Octavi...
Valneva SE , a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Val...
Moderna, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individua...
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with A...
© 2025 Biopharma Boardroom. All Rights Reserved.
